The increasing complexity of cancer chemotherapy heightens the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy. It will also serve as a review of various agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
KishJ., DrelichmanA., JacobsJ.Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck.Cancer Treat Rep.1982; 66(3): 471–474.
2.
KishJ.A., WeaverA., JacobsJ., CummingsG., Al-SarrafM.Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck.Cancer.1984; 53(9): 1819–1824.
3.
RooneyM., KishJ., JacobsJ.Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin.Cancer.1985; 55(5): 1123–1128.
4.
MercierR.J., NealG.D., MattoxD.E., GatesG.A., PomeroyT.C., Von HoffD.D.Cisplatin and 5-fluorouracil chemotherapy in advanced or recurrent squamous cell carcinoma of the head and neck.Cancer.1987; 60(11): 2609–2612.
5.
JacobsC., LymanG., Velez-GarciaE.A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.J Clin Oncol.1992; 10(2): 257–263.
6.
ForastiereA.A., MetchB., SchullerD.E.Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: A Southwest Oncology Group study.J Clin Oncol.1992; 10(8): 1245–1251.
7.
PooleM.E., SailerS.L., RosenmanJ.G.Chemoradiation for locally advanced squamous cell carcinoma of the head and neck for organ preservation and palliation.Arch Otolaryngol Head Neck Surg.2001; 127(12): 1446–1450.
8.
ArgirisA., LiY., MurphyB.A., LangerC.J., ForastiereA.A.Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.J Clin Oncol.2004; 22(2): 262–268.
9.
GibsonM.K., LiY., MurphyB.Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.J Clin Oncol.2005; 23(15): 3562–3567.
10.
DeckerD.A., DrelichmanA., JacobsJ.Adjuvant chemotherapy with cisdiamminodichloroplatinum II and 120hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neck.Cancer.1983; 51(8): 1353–1355.
11.
DasmahapatraK.S., CitrinP., HillG.J., YeeR., Mohit-TabatabaiM.A., RushB.F.A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous-cell cancer of the head and neck.J Clin Oncol.1985; 3(11): 1486–1489.
12.
RowlandK.M., TaylorS.G., SpiersA.S.D.Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: an Eastern Cooperative Oncology Group Pilot Study.Cancer Treat Rep.1986; 70(4): 461–464.
13.
ChoksiA.J., HongW.K., DimeryI.W., JamesP., GuillamondeguiO.M., ByersR.M.Continuous cisplatin (24-hour) and 5-fluorouracil (120-hour) infusion in recurrent head and neck squamous cell carcinoma.Cancer.1988; 61(5): 909–912.
14.
ConinxP., NascaS., LebrunD.Sequential trial of initial chemotherapy for advanced cancer of the head and neck. DDP versus DDP + 5-fluorouracil.Cancer.1988; 62(9): 1888–1892.
15.
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.The Department of Veterans Affairs Laryngeal Cancer Study Group.N Engl J Med.1991; 324(24): 1685–1690.
16.
VokesE.E., MickR., LesterE.P., PanjeW.R., WeichselbaumR.R.Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution.J Clin Oncol.1991; 9(8): 1376–1384.
17.
Bjork-ErikssonT., MerckeC., PetrusonB., EkholmS.Potential impact on tumor control and organ preservation with cisplatin and 5-fluorouracil for patients with advanced tumors of the paranasal sinuses and nasal fossa. A prospective pilot study.Cancer.1992; 70(11): 2615–2620.
18.
DimeryI.W., PetersL.J., GoepfertH.Effectiveness of combined induction chemotherapy and radiotherapy in advanced nasopharyngeal carcinoma.J Clin Oncol.1993; 11(10): 1919–1928.
19.
TaylorSG4th, MurthyA.K., VannetzelJ.M.Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.J Clin Oncol.1994; 12(2): 385–395.
20.
PaccagnellaA., OrlandoA., MarchioriC.Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo.J Natl Cancer Inst.1994; 86(4): 265–272.
21.
ClavelM., VermorkenJ.B., CognettiF.Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group.Ann Oncol.1994; 5(6): 521–526.
22.
De AndresL., BrunetJ., Lopez-PousaA.Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer.J Clin Oncol.1995; 13(6): 1493–1500.
23.
TaylorSG4th, MurthyA.K., ShowelJ.L.Improved control in advanced head and neck cancer with simultaneous radiation and cisplatin/5-FU chemotherapy.Cancer Treat Rep.1985; 69(9): 933–939.
24.
TaylorSG4th, MurthyA.K., CaldarelliD.D.Combined simultaneous cisplatin/fluorouracil chemotherapy and split course radiation in head and neck cancer.J Clin Oncol.1989; 7(7): 846–856.
25.
MerlanoM., TatarekR., GrimaldiA., MargarinoG., RossoR.Phase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule.Cancer Treat Rep.1985; 69(9): 961–964.
26.
MerlanoM., GrimaldiA., BrunettiI.Simultaneous cisplatin and 5-fluorouracil as second-line treatment of head and neck cancer.Cancer Treat Rep.1987; 71(5): 485–488.
27.
CorvoR., BenassoM., SanguinetiG.Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck: results from a phase III randomized trial.Cancer.2001; 92(11): 2856–2867.
28.
MerlanoM., VitaleV., RossoR.Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy.N Engl J Med.1992; 327(16): 1115–1121.
29.
AmreinP.C., WeitzmanS.A.Treatment of squamous-cell carcinoma of the head and neck with cisplatin and 5-fluorouracil.J Clin Oncol.1985; 3(12): 1632–1639.
30.
AdelsteinD.J., LiY., AdamsG.L.An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.J Clin Oncol.2003 Jan 1;21(1): 92–98.
31.
AdelsteinD.J., SharanV.M., EarleA.S.Chemoradiotherapy as initial management in patients with squamous cell carcinoma of the head and neck.Cancer Treat Rep.1986; 70(6): 761–767.
32.
AdelsteinD.J., KalishL.A., AdamsG.L.Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study.J Clin Oncol.1993; 11(11): 2136–2142.
33.
ParedesJ., HongW.K., FelderT.B.Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck.J Clin Oncol.1988; 6(6): 955–962.
34.
BernalA.G., CruzJ.J., SanchezP.Four-day continuous infusion of cisplatin and 5-fluorouracil in head and neck cancer.Cancer.1989; 63(10): 1927–1930.
35.
DenhamJ.W., AbbottR.L.Concurrent cisplatin, infusional fluorouracil, and conventionally fractionated radiation therapy in head and neck cancer: dose-limiting mucosal toxicity.J Clin Oncol.1991; 9(3): 458–463.
36.
ArcangeliG., SaracinoB., DanesiD.T.Accelerated hyperfractionated radiotherapy and concurrent protracted venous infusion chemotherapy in locally advanced head and neck cancer.Am J Clin Oncol.2002; 25(5): 431–437.
37.
BrocksteinB.E., VokesE.E.Chemotherapy for head and neck cancer. Available at: www.uptodate.com. Accessed on June 14, 2005.
38.
GregoireV., BeauduinM., HumbletY.A phase I-II trial of induction chemotherapy with carboplatin and fluorouracil in locally advanced head and neck squamous cell carcinoma: a report from the UCL-Oncology Group, Belgium.J Clin Oncol.1991; 9(8): 1385–1392.
39.
ForastiereA.A., NataleR.B., TakasugiB.J., GorenM.P., VogelW.C., Kudla-HatchV.A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.J Clin Oncol.1987; 5(2): 190–196.
40.
GreenbergB., AhmannF., GarewalH.Neoadjuvant therapy for advanced head and neck cancer with allopurinol-modulated high dose 5-fluorouracil and cisplatin. A phase I-II study.Cancer.1987; 59(11): 1860–1865.
41.
VokesE.E., HarafD.J., MickR., McEvillyJ.M., WeichselbaumR.R.Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.J Clin Oncol.1994; 12(11): 2351–2359.
42.
SchneiderM., EtienneM.C., MilanoG.Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.J Clin Oncol.1995; 13(7): 1656–1662.
43.
HussainM., BenedettiJ., SmithR.E., RodriguezG.I., SchullerD., EnsleyJ.Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.Cancer.1995; 76(7): 1233–1237.
44.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. Available at http://www.nccn.org/. Accessed on June 8, 2005.
45.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy.J Clin Oncol.1997; 15(1): 103–109.
46.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.Gynecol Oncol.1993; 50(2): 147–158.
LymanG.H.Balancing the benefits and costs of colony-stimulating factors: a current perspective.Semin Oncol.2003; 30(suppl 13): 10–17.
52.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.J Clin Oncol.2000; 18(20): 3558–3585.
53.
LarsonD.L.Treatment of tissue extravasation by antitumor agents.Cancer.1982; 49(9): 1796–1799.
54.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75(3): 397–402.
55.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury.Hosp Pharm.2000; 35(1): 57–74.
56.
BensonA.B.3rd, AjaniJ.A., CatalanoR.B.Recommended guidelines for the treatment of cancer treatment-induced diarrhea.J Clin Oncol.2004; 22(4): 2918–2926.
57.
PattersonW.P., ReamsG.P.Renal and electrolyte abnormalities due to chemotherapy. In: PerryM.C., ed. The Chemotherapy Sourcebook.3rd ed.Philadelphia, PA: Lippincott Williams & Wilkins; 2001: 494–504.
58.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.Cancer Treat Rev.1995; 21: 33–64.
59.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapy.Oncologist.2001; 6(2): 162–176.
60.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic agents. In: PerryM.C., ed. The Chemotherapy Sourcebook.3rd ed. Perry MC, ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001: 483–493.
